Login / Signup

Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.

Ruba Kal OmarAnna HagströmGustav Stålhammar
Published in: Trials (2023)
Our trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EudraCT 2022-500,307-49-00). Our trial registration number is NCT05502900, and the date of registration is August 16, 2022.
Keyphrases
  • phase iii
  • open label
  • phase ii
  • clinical trial
  • randomized controlled trial
  • study protocol
  • phase ii study
  • double blind
  • placebo controlled
  • healthcare
  • early stage
  • drug administration
  • rectal cancer